NanoViricides, Inc. (NYSE American: NNVC) announced continued progress in advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial. The trial will evaluate an oral gummies formulation as a treatment for the ongoing Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). According to the company, the proposed clinical trial has been approved by the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions.
NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies are difficult to deploy. The company highlighted the continued expansion of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine currently exists for the Bundibugyo strain.
NanoViricides believes NV-387’s broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains. The same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country for that study. This development underscores the potential of NV-387 to address urgent public health needs in regions with limited healthcare infrastructure.
The significance of this announcement lies in the potential impact on the DRC and global health. With no approved treatments for Bundibugyo ebolavirus, the availability of an oral therapy could drastically improve outbreak management. Oral formulations are easier to distribute and administer in remote areas, reducing the burden on healthcare workers and increasing patient compliance. If successful, NV-387 could become a critical tool in controlling future Ebola outbreaks.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for respiratory infections including RSV, COVID-19, and influenza, as well as Mpox and other viral diseases. The company’s platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/LaNwF.
